Oppenheimer analyst Leland Gershell weighed in on AcelRx Pharmaceuticals (NASDAQ: ACRX) following the FDA briefing documents, saying they read "positively ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE